Rebecca Araujo

DocwireNews

A <a href="https://onlinelibrary.wiley.com/doi/10.1111/bjh.17302">study</a> published in the British Journal of Haematology assessed updated survival data from a phase II trial of melphalan flufenamide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).Melphalan flufenamide (melflufen) is a peptide-drug conjugate currently <a href="https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/recent-fda-approvals-for-multiple-myeloma-and-what-to-expect-from-treatments-in-development/" target="_blank" rel="noopener noreferrer">under review</a> by the U.S. Food and Drug Administration for the treatment of RRMM.The open-label, multicenter, phase I/II O-12-M1 trial assessed patients with RRMM who received at least two prior lines of therapy, including lenalidomide and bortezomib. A total of 45 patients received one dose of melflufen 40 mg intravenously plus once weekly dexamethasone 40 mg orally, for up to eight 28-day cycles. Follow-up was conducted every three months for a median 28 months.Overall, the combination demonstrated durable responses at first data cutoff. The overall response rate was 31%, with a median response duration of 8.4 months (95% confidence interval [CI], 4.6-9.6 months). Median progression-free survival (PFS) and overall survival (OS) were 5.7 and 20.7 months, respectively. The most common grade 3/4 adverse events (AEs) were thrombocytopenia and neutropenia. Non-hematological AEs were infrequent, and no severe bleeding events occurred.About half (49%) of patients were still alive at time of data cutoff, so a protocol amendment was added for an updated OS evaluation. Nineteen patients were reevaluated, none of whom remained on treatment. At a median follow-up of 46 months, median OS for the entire population remained consistent at 20.7 months (95% CI, 11.8-41.3). Median PFS also remained unchanged at 5.7 months (95% CI, 3.7-9.2). Median time&#8208;to&#8208;next treatment was 7.9 months.In a post-hoc analysis, median OS for patients with International Staging System (ISS) stage I, II, and III RRMM at baseline was not met, 18.7 months (95% CI, 6.1-41.3), and 5.0 months (95% CI, 1.7-10.0), respectively. Patients who achieved at least a partial response had a median OS of 21.1 months, and those who achieved stable disease after treatment had a median OS of 47.1 months.&ldquo;In conclusion, the results of the present O&#8208;12&#8208;M1 long&#8208;term survival analysis in the context of a mature phase I/II study suggest that melflufen plus dexamethasone treatment can lead to long&#8208;term benefit in patients with advanced RRMM in whom other available therapies have failed,&rdquo; the authors wrote.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

New Data on Melflufen Combo for Myeloma Shows Durable Response

Oncology

A study published in the British Journal of Haematology assessed updated survival data from a phase II trial of melphalan flufenamide plus dexamethasone in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe